BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management.BMJ. 2020;370:m2687. [PMID: 32928750 DOI: 10.1136/bmj.m2687] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Gusev E, Solomatina L, Zhuravleva Y, Sarapultsev A. The Pathogenesis of End-Stage Renal Disease from the Standpoint of the Theory of General Pathological Processes of Inflammation. Int J Mol Sci 2021;22:11453. [PMID: 34768884 DOI: 10.3390/ijms222111453] [Reference Citation Analysis]
2 Nakatsuji Y, Yoshizawa M, Ohyama S. Effectiveness of a pleuroperitoneal shunt for refractory hepatic hydrothorax that appeared after ligation of a communicating hydrocele. BMJ Case Rep 2021;14:e242681. [PMID: 33972307 DOI: 10.1136/bcr-2021-242681] [Reference Citation Analysis]
3 Nassar M, Nso N, Medina L, Ghernautan V, Novikov A, El-Ijla A, Soliman KM, Kim Y, Alfishawy M, Rizzo V, Daoud A. Liver kidney crosstalk: Hepatorenal syndrome. World J Hepatol 2021; 13(9): 1058-1068 [PMID: 34630874 DOI: 10.4254/wjh.v13.i9.1058] [Reference Citation Analysis]
4 Subedi A, Suresh Kumar VC, Sharma Subedi A, Sapkota B. A Review of Hepatorenal Syndrome. Cureus 2021;13:e16084. [PMID: 34367745 DOI: 10.7759/cureus.16084] [Reference Citation Analysis]
5 Eknoyan G, Epstein M. Hepatorenal syndrome: a historical appraisal of its origins and conceptual evolution. Kidney Int 2021;99:1321-30. [PMID: 33781792 DOI: 10.1016/j.kint.2021.02.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kulkarni AV, Arab JP, Premkumar M, Benítez C, Tirumalige Ravikumar S, Kumar P, Sharma M, Reddy DN, Simonetto DA, Rao PN. Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives. Liver Int 2020;40:2888-905. [DOI: 10.1111/liv.14703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Fang Y, Zhu H, Gao C, Gu Y, Liu Y, Yuan Y, Wu X. Value of shear wave elastography in predicting hepatorenal syndrome in patients with liver cirrhosis and ascites. Int J Clin Pract 2021;75:e14811. [PMID: 34490949 DOI: 10.1111/ijcp.14811] [Reference Citation Analysis]
8 Téllez L, Guerrero A. Management of Liver Decompensation in Advanced Liver Disease (Renal Impairment, Liver Failure, Adrenal Insufficiency, Cardiopulmonary Complications). Clin Drug Investig 2022. [PMID: 35522396 DOI: 10.1007/s40261-022-01149-3] [Reference Citation Analysis]
9 Kaewput W, Thongprayoon C, Dumancas CY, Kanduri SR, Kovvuru K, Kaewput C, Pattharanitima P, Petnak T, Lertjitbanjong P, Boonpheng B, Wijarnpreecha K, Zabala Genovez JL, Vallabhajosyula S, Jadlowiec CC, Qureshi F, Cheungpasitporn W. In-hospital mortality of hepatorenal syndrome in the United States: Nationwide inpatient sample. World J Gastroenterol 2021; 27(45): 7831-7843 [PMID: 34963745 DOI: 10.3748/wjg.v27.i45.7831] [Reference Citation Analysis]
10 Solé C, Ma AT, Solà E, Carol M, Fabrellas N, Juanola A, Napoleone L, Gratacós-Ginès J, Bassegoda O, Cervera M, Pérez M, Rubio AB, Avitabile E, Morales-Ruiz M, Graupera I, Pose E, Kamath PS, Ginès P. Sequential changes in urinary biomarker levels in patients with cirrhosis and severe hepatorenal syndrome. Liver Int 2021;41:2729-32. [PMID: 34569697 DOI: 10.1111/liv.15069] [Reference Citation Analysis]
11 Ji Y, Li L. Lower serum chloride concentrations are associated with increased risk of mortality in critically ill cirrhotic patients: an analysis of the MIMIC-III database. BMC Gastroenterol 2021;21:200. [PMID: 33933032 DOI: 10.1186/s12876-021-01797-3] [Reference Citation Analysis]
12 Abdurashitov AS, Prikhozhdenko ES, Mayorova OA, Plastun VO, Gusliakova OI, Shushunova NA, Kulikov OA, Tuchin VV, Sukhorukov GB, Sindeeva OA. Optical coherence microangiography of the mouse kidney for diagnosis of circulatory disorders. Biomed Opt Express 2021;12:4467-77. [PMID: 34457426 DOI: 10.1364/BOE.430393] [Reference Citation Analysis]
13 Bejjani A, Zhang Y, Behrens A, Murray B, Shah N. Droxidopa in the Management of Hepatorenal Syndrome. J Pharm Pract 2022;:8971900221087974. [PMID: 35426352 DOI: 10.1177/08971900221087974] [Reference Citation Analysis]
14 Sanchez LO, Francoz C. Global strategy for the diagnosis and management of acute kidney injury in patients with liver cirrhosis. United European Gastroenterol J 2021;9:220-8. [PMID: 33337286 DOI: 10.1177/2050640620980713] [Reference Citation Analysis]
15 Menè P, Stoppacciaro A, Lai S, Festuccia F. Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges. IJNRD 2022;Volume 15:173-83. [DOI: 10.2147/ijnrd.s280179] [Reference Citation Analysis]
16 da Silveira F, Soares PHR, Marchesan LQ, da Fonseca RSA, Nedel WL. Assessing the prognosis of cirrhotic patients in the intensive care unit: What we know and what we need to know better. World J Hepatol 2021; 13(10): 1341-1350 [PMID: 34786170 DOI: 10.4254/wjh.v13.i10.1341] [Reference Citation Analysis]
17 Scurt FG, Bose K, Canbay A, Mertens PR, Chatzikyrkou C. [Chronic kidney injury in patients with liver diseases - Reappraising pathophysiology and treatment options]. Z Gastroenterol 2021;59:560-79. [PMID: 33728618 DOI: 10.1055/a-1402-1502] [Reference Citation Analysis]
18 Premkumar M, Anand AC. Overview of Complications in Cirrhosis. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.04.021] [Reference Citation Analysis]
19 Ayares G, Idalsoaga F, Díaz LA, Arnold J, Arab JP. Current Medical Treatment for Alcohol-Associated Liver Disease. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.02.001] [Reference Citation Analysis]
20 Zou W, Shi B, Zeng T, Zhang Y, Huang B, Ouyang B, Cai Z, Liu M. Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking. Front Pharmacol 2021;12:746208. [PMID: 34912216 DOI: 10.3389/fphar.2021.746208] [Reference Citation Analysis]
21 Li J, Gong X. Tetramethylpyrazine: An Active Ingredient of Chinese Herbal Medicine With Therapeutic Potential in Acute Kidney Injury and Renal Fibrosis. Front Pharmacol 2022;13:820071. [DOI: 10.3389/fphar.2022.820071] [Reference Citation Analysis]
22 Sasso R, Abou Yassine A, Deeb L. Predictors of Development of Hepatorenal Syndrome in Hospitalized Cirrhotic Patients with Acute Kidney Injury. J Clin Med 2021;10:5621. [PMID: 34884323 DOI: 10.3390/jcm10235621] [Reference Citation Analysis]
23 Su WY, Chu NS, Huang JC, Wu PY, Lee WH, Liu YH, Chen SC, Su HM. Low Albumin, Low Bilirubin, and High Alfa-Fetoprotein Are Associated with a Rapid Renal Function Decline in a Large Population Follow-Up Study. J Pers Med 2021;11:781. [PMID: 34442425 DOI: 10.3390/jpm11080781] [Reference Citation Analysis]
24 Chandna S, Zarate ER, Gallegos-Orozco JF. Management of Decompensated Cirrhosis and Associated Syndromes. Surg Clin North Am 2022;102:117-37. [PMID: 34800381 DOI: 10.1016/j.suc.2021.09.005] [Reference Citation Analysis]
25 Simbrunner B, Trauner M, Reiberger T, Mandorfer M. Recent advances in the understanding and management of hepatorenal syndrome. Fac Rev 2021;10:48. [PMID: 34131658 DOI: 10.12703/r/10-48] [Reference Citation Analysis]
26 Mauro E, Garcia-Olveira L, Gadano A. End-stage liver disease: Management of hepatorenal syndrome. Liver Int 2021;41 Suppl 1:119-27. [PMID: 34155791 DOI: 10.1111/liv.14866] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Liu S, Meng Q, Xu Y, Zhou J. Hepatorenal syndrome in acute-on-chronic liver failure with acute kidney injury: more questions requiring discussion. Gastroenterol Rep (Oxf) 2021;9:505-20. [PMID: 34925848 DOI: 10.1093/gastro/goab040] [Reference Citation Analysis]
28 He HM, He C, Zhang SC, You ZB, Lin XQ, Luo MQ, Lin MQ, Guo YS, Zheng WP, Lin KY. Predictive value of aspartate aminotransferase-to-alanine aminotransferase ratio for contrast-associated acute kidney injury in patients undergoing elective percutaneous coronary intervention. J Cardiol 2021:S0914-5087(21)00319-1. [PMID: 34857433 DOI: 10.1016/j.jjcc.2021.11.009] [Reference Citation Analysis]
29 Hu SC, Xia H, Ye QQ, Xia C, Xu YL, Xiang XJ, Ma HZ, Gao XF, Chen HB. Reversal of hepatorenal syndrome and kidney recovery: When renal has more to offer. Semin Dial 2022. [PMID: 35460110 DOI: 10.1111/sdi.13083] [Reference Citation Analysis]
30 Belcher JM, Parada XV, Simonetto DA, Juncos LA, Karakala N, Wadei HM, Sharma P, Regner KR, Nadim MK, Garcia-Tsao G, Velez JCQ, Parikh SM, Chung RT, Allegretti AS; HRS-HARMONY study investigators. Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward. Am J Kidney Dis 2021:S0272-6386(21)00890-8. [PMID: 34606933 DOI: 10.1053/j.ajkd.2021.08.016] [Reference Citation Analysis]